

**S9 Table.** Polymorphisms associated with gastric cancer susceptibility with p-value  $<5 \times 10^{-5}$  conditioning on *PSCA* gene in discovery phase and results of the validation phase and meta-analysis in female

Character				Phase I (GWAS phase)					Phase II (Validation phase)					Meta-analysis	
SNP	CHR	BP	MA	No.	MAF in cases	MAF in controls	Odds ratio	p-value	No.	MAF in cases	MAF in controls	Odds ratio	p-value	Odds ratio	p-value
rs12233126	2	100012200	A	734	0.38	0.27	1.77 (1.34-2.35)	6.27E-05	2,311	0.28	0.28	1.02 (0.83-1.26)	0.8231	1.24 (1.05-1.46)	0.0109
rs28382949	2	100028112	T	734	0.38	0.27	1.77 (1.34-2.35)	6.27E-05	2,312	0.28	0.28	1.02 (0.83-1.26)	0.8259	1.24 (1.05-1.46)	0.0111
rs72956387	2	100028890	G	734	0.38	0.27	1.77 (1.34-2.35)	6.27E-05	2,312	0.28	0.28	1.02 (0.83-1.26)	0.8259	1.24 (1.05-1.46)	0.0111
rs11123785	2	100011675	T	733	0.38	0.27	1.77 (1.34-2.34)	6.61E-05	2,311	0.28	0.28	1.02 (0.83-1.26)	0.8231	1.24 (1.05-1.46)	0.0112
rs2242036	2	100010685	G	733	0.38	0.27	1.77 (1.34-2.34)	6.61E-05	2,312	0.28	0.28	1.02 (0.83-1.26)	0.8196	1.24 (1.05-1.46)	0.0112
rs111673703	11	130009474	T	745	0.11	0.05	2.49 (1.59-3.91)	7.08E-05	2,294	0.07	0.06	1.09 (0.75-1.59)	0.6472	1.53 (1.15-2.05)	0.0037
rs1979687	11	11979674	G	706	0.29	0.43	0.57 (0.43-0.75)	9.67E-05	2,312	0.39	0.40	0.97 (0.8-1.17)	0.7303	0.82 (0.7-0.96)	0.0151
rs10463885	5	130650168	G	710	0.06	0.02	4.17 (2.03-8.55)	9.73E-05	2,244	0.02	0.03	0.88 (0.48-1.6)	0.6665	1.68 (1.05-2.66)	0.0289

MA, minor allele; MAF, minor allele frequency.